SCHEMBL5895486

SCHEMBL5895486

O=C(CCC1CCCC1)N/C(=C\c1ccc(Oc2ccc(Cl)cc2Cl)cc1)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 3/20 0.51
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
ALDH1A1 P00352 4/20 0.41
LMNA P02545 1/20 0.41
HPGD P15428 3/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MRGPRX4 Q96LA9 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
POLB P06746 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
KDM4E B2RXH2 1/20 0.37
CHRM1 P11229 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5895506 1.00 FFAR1 (0.51) FFAR1NPC1RAB9AALDH1A1LMNA
SCHEMBL5895496 1.00 FFAR1 (0.51) FFAR1NPC1RAB9AALDH1A1LMNA
SCHEMBL5895900 0.91 NPSR1 (0.44) FFAR1NPC1RAB9AALDH1A1LMNA
SCHEMBL5897273 0.91 NPC1 (0.43) FFAR1NPC1RAB9AALDH1A1HPGD
SCHEMBL5896603 0.91 NPC1 (0.45) FFAR1NPC1RAB9AALDH1A1HPGD
SCHEMBL5897262 0.91 NPC1 (0.43) FFAR1NPC1RAB9AALDH1A1HPGD
SCHEMBL5895333 0.91 HPGD (0.43) FFAR1ALDH1A1LMNAHPGDL3MBTL1
SCHEMBL5895908 0.91 NPSR1 (0.44) FFAR1NPC1RAB9AALDH1A1LMNA
SCHEMBL5896595 0.91 NPC1 (0.45) FFAR1NPC1RAB9AALDH1A1HPGD
SCHEMBL5895919 0.91 NPSR1 (0.44) FFAR1NPC1RAB9AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7041690-B2 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY, LLC (US) 2006-05-09 US disclosed
US-20060004063-A1 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY, LLC 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004063-A1 Inhibitors of HCV NS5B polymerase POLRMT, EIF5B, POLI FFAR1 3738/4885NPC1 131/4885RAB9A 1149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.